Brewster

Researchers are evaluating the safety and effects of the study medicine PF-07799544, alone or combined with PF-07799933, as a potential cancer treatment for adults with advanced solid tumors. This trial involves participants with metastatic or recurrent solid tumors (excluding colorectal cancer) that have a BRAF V600 mutation and who have received prior cancer treatments as assigned. Phase 1a of the study, which involved PF-07799544 alone, is closed for enrollment, and the current Phase 1b focuses on combination therapy with both medicines. All participants in Phase 1b will take both study medicines as tablets by mouth twice daily at home. Treatment will continue until the cancer no longer responds, unacceptable side effects occur, or for up to two years. Participants may continue therapy beyond two years if appropriate. The study is designed to monitor the safety and potential effectiveness of these treatments in this patient population. Participants will be assessed for dose limiting toxicities, treatment-emergent adverse events, and clinically significant changes in laboratory tests, vital signs, and physical exams during the first 21 days and up to 28 days after the last dose. The overall response rate will be measured for up to two years. Safety and treatment effects will be carefully monitored throughout, with the goal of understanding how these medicines impact patients with BRAF-mutant advanced solid tumors.

Researchers are conducting a phase 3, multicenter, randomized, open-label study to compare treatments in patients with metastatic non-small cell lung cancer (NSCLC) who have developed secondary resistance to immune checkpoint inhibitor (ICI) therapy. The study focuses on patients positive for the HLA-A2 phenotype and includes both squamous and non-squamous types of NSCLC. Participants will be grouped based on cancer histology and their performance status to better understand treatment effects. Participants will be randomly assigned in a 2:1 ratio to receive either the experimental treatment OSE2101 or the standard treatment docetaxel. OSE2101 is a cancer vaccine made of nine specific peptide components targeting tumor-associated antigens, combined with an adjuvant to enhance immune response. Docetaxel, the control treatment, is a chemotherapy drug that disrupts cell division. The study uses an assay device to confirm HLA-A2 status before treatment allocation. During the average three-year study period, researchers will monitor overall survival, defined as the time from randomization until death. Patients will be regularly assessed for treatment response and safety. The trial aims to gather important data on the efficacy and tolerability of the OSE2101 vaccine compared to docetaxel in this patient population with metastatic NSCLC and secondary resistance to ICI therapy.